Argenx's Efgartigimod Becomes First Phase 3 Therapy To Show Statistically Significant, Clinically Meaningful Improvement In IMNM, A Subtype With No Approved Treatment
Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)Patient improvements observed early and sustained throughout study;
Argenx's new medicine passed an important test, showing it can help people with a rare muscle disease that had no treatment before. When a company proves a medicine really works in testing, it's a signal the medicine could eventually reach patients and create value.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.